Risk factors for community-associated multidrug-resistant Pseudomonas aeruginosa in veterans with spinal cord injury and disorder: a retrospective cohort study
Study design: Retrospective cohort study Objectives: To identify independent risk factors associated with community-associated multidrug-resistant Psedomonas aeruginosa (MDRPA) in a population of veterans with spinal cord injury and disorders (SCI/D). Setting: A total of 127 Veterans Affairs healthc...
Saved in:
Published in: | Spinal cord Vol. 55; no. 7; pp. 687 - 691 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
London
Nature Publishing Group UK
01-07-2017
Nature Publishing Group |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Study design:
Retrospective cohort study
Objectives:
To identify independent risk factors associated with community-associated multidrug-resistant
Psedomonas aeruginosa
(MDRPA) in a population of veterans with spinal cord injury and disorders (SCI/D).
Setting:
A total of 127 Veterans Affairs healthcare facilities.
Methods:
Laboratory results from 1 January 2012 to 31 December 2013 were collected, and MDRPA cultures were compared with non-MDRPA cultures.
Results:
One thousand four hundred forty-one cultures were collected from Veterans with SCI/D, including 227 cultures with MDRPA isolates. Characteristics associated with an increased odds of MDRPA include age 50–64 (adjusted odds ratio (aOR)=1.80, 95% confidence interval (CI)=1.13–2.87), MDRPA culture in the past 365 days (aOR=9.12, 95% CI=5.88–14.15) and carbapenem exposure in the past 90 days (aOR=2.56, 95% CI=1.35–4.87). In contrast, paraplegia was associated with a 53% decreased odds of MDRPA compared with those with tetraplegia (aOR=0.47, 95% CI=0.32–0.69).
Conclusions:
Risk factors for community-associated MDRPA include prior history of MDRPA and exposure to carbapenems. Awareness of these factors is important for targeted prevention and treatment of MDRPA in patients with SCI/D. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1362-4393 1476-5624 |
DOI: | 10.1038/sc.2017.7 |